{"id":"W2944461353","doi":"10.1158/1538-7445.sabcs18-p6-18-14","title":"Abstract P6-18-14: Patient-reported outcomes with ribociclib-based therapy in hormone receptor-positive, HER2-negative advanced breast cancer: results from the phase III MONALEESA-2, -3, and -7 trials","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Letrozole; Internal medicine; Goserelin; Fulvestrant; Anastrozole; Breast cancer; Clinical endpoint; Oncology; Cancer; Placebo; Aromatase inhibitor; Metastatic breast cancer; Progression-free survival; Palbociclib; Clinical trial; Chemotherapy; Estrogen receptor; Aromatase; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002422472,0.0007562051,0.001159364,0.0002950933,0.0002433066,0.0009991113,0.0005272854,0.0008039169,0.006926922],"category_scores_gemma":[0.002286609,0.0001625058,0.002334467,0.0005893708,0.0004283334,0.0007439964,0.0005300905,0.001890133,0.0008444726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004170869,"about_ca_system_score_gemma":0.0006192462,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000352247,"about_ca_topic_score_gemma":0.0007406203,"domain_scores_codex":[0.9986118,0.0008591203,0.0001122102,0.000165722,0.0001495658,0.0001015268],"domain_scores_gemma":[0.9979259,0.0004730907,0.0009679042,0.00009234464,0.0001568748,0.0003838951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7698521,0.004441134,0.05480985,0.003520532,0.01052043,0.0001462657,0.0001092091,0.001789844,0.004352091,0.000254421,0.01467447,0.1355297],"study_design_scores_gemma":[0.4591268,0.2047406,0.2815275,0.0008425443,0.01728722,0.001141167,0.0002230094,0.003200529,0.006227459,0.001122983,0.02441203,0.0001482103],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9383405,0.02871541,0.0008292691,0.002487066,0.0002924116,0.00125851,0.02160549,0.0001162387,0.006355002],"genre_scores_gemma":[0.9775624,0.005374053,0.0008926619,0.001020014,0.0004200303,0.001410933,0.0111425,0.00002746381,0.002149869],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006926922,"threshold_uncertainty_score":0.02317286,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07544344919931267,"score_gpt":0.4165428332646931,"score_spread":0.3410993840653804,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}